{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T11:00:06Z","timestamp":1782990006196,"version":"3.54.5"},"reference-count":61,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.xphs.2019.10.041","type":"journal-article","created":{"date-parts":[[2019,10,28]],"date-time":"2019-10-28T12:14:08Z","timestamp":1572264848000},"page":"558-565","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Subvisible Particles in IVIg Formulations Activate Complement in Human Serum"],"prefix":"10.1016","volume":"109","author":[{"given":"Carly F.","family":"Chisholm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Behnke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yekaterina","family":"Pokhilchuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley A.","family":"Frazer-Abel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore W.","family":"Randolph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.xphs.2019.10.041_bib1","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1136\/jnnp.73.2.148","article-title":"Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory","volume":"73","author":"Bertolotto","year":"2002","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.xphs.2019.10.041_bib2","first-page":"31","article-title":"Measurement of neutralizing antibodies to interferon beta in patients with multiple sclerosis","volume":"251","author":"Deisenhammer","year":"2004","journal-title":"J\u00a0Neurol"},{"issue":"13","key":"10.1016\/j.xphs.2019.10.041_bib3","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1212\/01.wnl.0000258545.73854.cf","article-title":"Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology","volume":"68","author":"Goodin","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.xphs.2019.10.041_bib4","first-page":"1","article-title":"Neutralizing antibodies to interferon beta in patients with multiple sclerosis: scientific background and clinical implications\u2013introduction","volume":"251","author":"Hartung","year":"2004","journal-title":"J\u00a0Neurol"},{"issue":"8","key":"10.1016\/j.xphs.2019.10.041_bib5","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/j.1468-1331.2005.01104.x","article-title":"Significance of neutralizing antibodies to interferon beta during treatment of multiple sclerosis: expert opinions based on the Proceedings of an International Consensus Conference","volume":"12","author":"Hartung","year":"2005","journal-title":"Eur J Neurol"},{"issue":"7","key":"10.1016\/j.xphs.2019.10.041_bib6","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S1474-4422(05)70117-4","article-title":"Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis","volume":"4","author":"Hemmer","year":"2005","journal-title":"Lancet Neurol"},{"issue":"11","key":"10.1016\/j.xphs.2019.10.041_bib7","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1212\/01.WNL.0000129265.73259.9E","article-title":"Neutralizing antibodies reduce the efficacy of beta IFN during treatment of multiple sclerosis","volume":"62","author":"Malucchi","year":"2004","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.xphs.2019.10.041_bib8","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/ajg.2011.103","article-title":"Assessing response and loss of response to biological therapies in IBD","volume":"106","author":"Yanai","year":"2011","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.xphs.2019.10.041_bib9","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/ajg.2012.363","article-title":"Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis","volume":"108","author":"Nanda","year":"2013","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"10.1016\/j.xphs.2019.10.041_bib10","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.cgh.2012.06.032","article-title":"Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease","volume":"10","author":"Ord\u00e1s","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.xphs.2019.10.041_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.MIB.0000436951.80898.6d","article-title":"Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"20","author":"O'Meara","year":"2014","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"10.1016\/j.xphs.2019.10.041_bib12","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1177\/1352458512460604","article-title":"Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis","volume":"19","author":"Vennegoor","year":"2013","journal-title":"Mult Scler"},{"issue":"3","key":"10.1016\/j.xphs.2019.10.041_bib13","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0022-3549(15)00180-X","article-title":"Subvisible particle content, formulation, and dose of an erythropoietin peptide mimetic product are associated with severe adverse postmarketing events","volume":"105","author":"Kotarek","year":"2016","journal-title":"J\u00a0Pharm Sci"},{"issue":"3","key":"10.1016\/j.xphs.2019.10.041_bib14","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jaip.2016.12.001","article-title":"Current knowledge and management of hypersensitivity reactions to monoclonal antibodies","volume":"5","author":"Picard","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.xphs.2019.10.041_bib15","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1177\/1078155218780514","article-title":"Severe first infusion reaction related to cetuximab in cancer patients in Arkansas","volume":"25","author":"Atwal","year":"2019","journal-title":"J\u00a0Oncol Pharm Pract"},{"issue":"7","key":"10.1016\/j.xphs.2019.10.041_bib16","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.3899\/jrheum.140538","article-title":"Incidence and management of infusion reactions to infliximab in a prospective real-world community registry","volume":"42","author":"Choquette","year":"2015","journal-title":"J\u00a0Rheumatol"},{"issue":"4","key":"10.1016\/j.xphs.2019.10.041_bib17","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S1567-5769(01)00006-6","article-title":"Formation of complement-activating particles in aqueous solutions of Taxol: possible role in hypersensitivity reactions","volume":"1","author":"Szebeni","year":"2001","journal-title":"Int Immunopharmacol"},{"issue":"2-3","key":"10.1016\/j.xphs.2019.10.041_bib18","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.tox.2005.07.023","article-title":"Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity","volume":"216","author":"Szebeni","year":"2005","journal-title":"Toxicology"},{"issue":"4","key":"10.1016\/j.xphs.2019.10.041_bib19","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1166\/jbn.2009.1045","article-title":"Complement: alive and kicking nanomedicines","volume":"5","author":"Andersen","year":"2009","journal-title":"J\u00a0Biomed Nanotechnol"},{"issue":"12","key":"10.1016\/j.xphs.2019.10.041_bib20","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.addr.2011.06.002","article-title":"Material properties in complement activation","volume":"63","author":"Moghimi","year":"2011","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"10.1016\/j.xphs.2019.10.041_bib21","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.nano.2013.02.011","article-title":"Nanomedicine and the complement paradigm","volume":"9","author":"Moghimi","year":"2013","journal-title":"Nanomedicine"},{"issue":"2","key":"10.1016\/j.xphs.2019.10.041_bib22","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.molimm.2014.06.038","article-title":"Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals","volume":"61","author":"Szebeni","year":"2014","journal-title":"Mol Immunol"},{"key":"10.1016\/j.xphs.2019.10.041_bib23","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.smim.2017.08.013","article-title":"Nanoparticles and innate immunity: new perspectives on host defence","volume":"34","author":"Boraschi","year":"2017","journal-title":"Semin Immunol"},{"issue":"3","key":"10.1016\/j.xphs.2019.10.041_bib24","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/eji.201040355","article-title":"Complement fragments C3a and C5a: the salt and pepper of the immune response","volume":"40","author":"Sacks","year":"2010","journal-title":"Eur J Immunol"},{"issue":"14","key":"10.1016\/j.xphs.2019.10.041_bib25","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1016\/j.molimm.2009.04.027","article-title":"The role of the anaphylatoxins in health and disease","volume":"46","author":"Klos","year":"2009","journal-title":"Mol Immunol"},{"issue":"1-2","key":"10.1016\/j.xphs.2019.10.041_bib26","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1081\/LPR-120004790","article-title":"Role of complement activation in hypersensitivity reactions to doxil and hynic PEG liposomes: experimental and clinical studies","volume":"12","author":"Szebeni","year":"2002","journal-title":"J\u00a0Liposome Res"},{"issue":"9","key":"10.1016\/j.xphs.2019.10.041_bib27","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1093\/annonc\/mdg374","article-title":"Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions","volume":"14","author":"Chanan-Khan","year":"2003","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.xphs.2019.10.041_bib28","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.nano.2015.11.019","article-title":"Factor H inhibits complement activation induced by liposomal and micellar drugs and the therapeutic antibody rituximab in\u00a0vitro","volume":"12","author":"Meszaros","year":"2016","journal-title":"Nanomedicine"},{"issue":"1","key":"10.1016\/j.xphs.2019.10.041_bib29","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/antib7010014","article-title":"Infusion reactions associated with the medical application of monoclonal antibodies: the role of complement activation and possibility of inhibition by factor H","volume":"7","author":"Fulop","year":"2018","journal-title":"Antibodies (Basel)"},{"issue":"4","key":"10.1016\/j.xphs.2019.10.041_bib30","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1046\/j.1365-2141.2001.03166.x","article-title":"Complement activation plays a key role in the side-effects of rituximab treatment","volume":"115","author":"van der Kolk","year":"2001","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.xphs.2019.10.041_bib31","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1002\/aic.11252","article-title":"Engineering challenges of protein formulations","volume":"53","author":"Randolph","year":"2007","journal-title":"AIChE J"},{"key":"10.1016\/j.xphs.2019.10.041_bib32","first-page":"22","article-title":"A risk-based approach to immunogenicity concerns of therapeutic protein products, part 1: Considering consequences of the immune response to a protein","volume":"17","author":"Rosenberg","year":"2004","journal-title":"BioPharm International"},{"key":"10.1016\/j.xphs.2019.10.041_bib33","first-page":"15","article-title":"Immunogenicity of biological therapeutics: a hierarchy of concerns","volume":"112","author":"Rosenberg","year":"2003","journal-title":"Dev Biol (Basel)"},{"issue":"3","key":"10.1016\/j.xphs.2019.10.041_bib34","doi-asserted-by":"crossref","first-page":"E501","DOI":"10.1208\/aapsj080359","article-title":"Effects of protein aggregates: an immunologic perspective","volume":"8","author":"Rosenberg","year":"2006","journal-title":"AAPS J"},{"issue":"9","key":"10.1016\/j.xphs.2019.10.041_bib35","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1002\/jps.21719","article-title":"Silicone oil- and agitation-induced aggregation of a monoclonal antibody in aqueous solution","volume":"98","author":"Thirumangalathu","year":"2009","journal-title":"J\u00a0Pharm Sci"},{"issue":"6","key":"10.1016\/j.xphs.2019.10.041_bib36","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1002\/jps.23973","article-title":"Protein aggregation and particle formation in prefilled glass syringes","volume":"103","author":"Gerhardt","year":"2014","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.xphs.2019.10.041_bib37","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1016\/j.xphs.2018.03.016","article-title":"Protein nanoparticles promote microparticle formation in intravenous immunoglobulin solutions during freeze-thawing and agitation stresses","volume":"107","author":"Pardeshi","year":"2018","journal-title":"J\u00a0Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2019.10.041_bib38","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1167\/iovs.10-6431","article-title":"Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling","volume":"52","author":"Liu","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"10.1016\/j.xphs.2019.10.041_bib39","doi-asserted-by":"crossref","first-page":"317","DOI":"10.5731\/pdajpst.2016.007278","article-title":"Performance stability of silicone oxide-coated plastic parenteral vials","volume":"71","author":"Weikart","year":"2017","journal-title":"PDA J Pharm Sci Technol"},{"key":"10.1016\/j.xphs.2019.10.041_bib40","series-title":"Immunobiology: The Immune System in Health","first-page":"37","author":"Janeway","year":"2005"},{"issue":"10","key":"10.1016\/j.xphs.2019.10.041_bib41","doi-asserted-by":"crossref","first-page":"4347","DOI":"10.1002\/jps.21328","article-title":"Shaken, not stirred: mechanical stress testing of an IgG1 antibody","volume":"97","author":"Kiese","year":"2008","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.xphs.2019.10.041_bib42","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/j.xphs.2018.04.005","article-title":"Postproduction handling and administration of protein pharmaceuticals and potential instability issues","volume":"107","author":"Nejadnik","year":"2018","journal-title":"J\u00a0Pharm Sci"},{"issue":"6","key":"10.1016\/j.xphs.2019.10.041_bib43","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.xphs.2017.02.029","article-title":"Potential issues with the handling of biologicals in a hospital","volume":"106","author":"Jiskoot","year":"2017","journal-title":"J\u00a0Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2019.10.041_bib44","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s11095-017-2341-x","article-title":"The impact of inadequate temperature storage conditions on aggregate and particle formation in drugs containing tumor necrosis factor-alpha inhibitors","volume":"35","author":"Vlieland","year":"2018","journal-title":"Pharm Res"},{"issue":"4","key":"10.1016\/j.xphs.2019.10.041_bib45","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/rheumatology\/kev394","article-title":"The majority of patients do not store their biologic disease-modifying antirheumatic drugs within the recommended temperature range","volume":"55","author":"Vlieland","year":"2016","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.xphs.2019.10.041_bib46","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0005-2736(01)00408-4","article-title":"Potentiation of liposome-induced complement activation by surface-bound albumin","volume":"1559","author":"Savay","year":"2002","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"10.1016\/j.xphs.2019.10.041_bib47","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2174\/156720105774370212","article-title":"Complement activation-related pseudoallergy caused by amphiphilic drug carriers: the role of lipoproteins","volume":"2","author":"Szebeni","year":"2005","journal-title":"Curr Drug Deliv"},{"issue":"2","key":"10.1016\/j.xphs.2019.10.041_bib48","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jconrel.2010.04.003","article-title":"Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: the challenges ahead","volume":"146","author":"Moghimi","year":"2010","journal-title":"J\u00a0Control Release"},{"issue":"12","key":"10.1016\/j.xphs.2019.10.041_bib49","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.addr.2011.06.008","article-title":"Complement monitoring of nanomedicines and implants","volume":"63","author":"Moghimi","year":"2011","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"10.1016\/j.xphs.2019.10.041_bib50","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2217\/nnm.11.169","article-title":"Interaction of nanoparticles with immunocompetent cells: nanosafety considerations","volume":"7","author":"Boraschi","year":"2012","journal-title":"Nanomedicine (Lond)"},{"issue":"3","key":"10.1016\/j.xphs.2019.10.041_bib51","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.bbrc.2015.06.177","article-title":"Complement activation as a bioequivalence issue relevant to the development of generic liposomes and other nanoparticulate drugs","volume":"468","author":"Szebeni","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.xphs.2019.10.041_bib52","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1124\/jpet.119.258012","article-title":"The interplay between blood proteins, complement, and macrophages on nanomedicine performance and responses","volume":"370","author":"Moghimi","year":"2019","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.xphs.2019.10.041_bib53","doi-asserted-by":"crossref","first-page":"015003","DOI":"10.1088\/1749-4699\/7\/1\/015003","article-title":"Physicochemical signatures of nanoparticle-dependent complement activation","volume":"7","author":"Thomas","year":"2014","journal-title":"Comput Sci Discov"},{"issue":"6176","key":"10.1016\/j.xphs.2019.10.041_bib54","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.1248943","article-title":"Complement is activated by IgG hexamers assembled at the cell surface","volume":"343","author":"Diebolder","year":"2014","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.xphs.2019.10.041_bib55","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1016\/j.biomaterials.2013.12.085","article-title":"Mediation of a non-proteolytic activation of complement component C3 by phospholipid vesicles","volume":"35","author":"Klapper","year":"2014","journal-title":"Biomaterials"},{"issue":"4","key":"10.1016\/j.xphs.2019.10.041_bib56","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ejps.2011.09.016","article-title":"Complement activation by polyethoxylated pharmaceutical surfactants: cremophor-EL, Tween-80 and Tween-20","volume":"45","author":"Weiszh\u00e1r","year":"2012","journal-title":"Eur J Pharm Sci"},{"issue":"5","key":"10.1016\/j.xphs.2019.10.041_bib57","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/PCC.0b013e3181d900ba","article-title":"Genetic variability in complement activation modulates the systemic inflammatory response syndrome in children","volume":"11","author":"Agbeko","year":"2010","journal-title":"Pediatr Crit Care Med"},{"issue":"21","key":"10.1016\/j.xphs.2019.10.041_bib58","doi-asserted-by":"crossref","first-page":"8761","DOI":"10.1073\/pnas.1019338108","article-title":"Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk","volume":"108","author":"Heurich","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.xphs.2019.10.041_bib59","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.it.2012.06.001","article-title":"The complotype: dictating risk for inflammation and infection","volume":"33","author":"Harris","year":"2012","journal-title":"Trends Immunol"},{"issue":"12","key":"10.1016\/j.xphs.2019.10.041_bib60","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.addr.2011.06.017","article-title":"Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention","volume":"63","author":"Szebeni","year":"2011","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"10.1016\/j.xphs.2019.10.041_bib61","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1515\/ejnm-2015-0026","article-title":"Variable association of complement activation by rituximab and paclitaxel in cancer patients in\u00a0vivo and in their screening serum in\u00a0vitro with clinical manifestations of hypersensitivity: a pilot study","volume":"7","author":"Kozma","year":"2015","journal-title":"Eur J Nanomed"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354919306781?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354919306781?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:38:14Z","timestamp":1758361094000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354919306781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0022354919306781"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2019.10.041","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Subvisible Particles in IVIg Formulations Activate Complement in Human Serum","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2019.10.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}